Collegium PharmaceuticalCOLL
COLL
About: Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Employees: 197
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
215% more call options, than puts
Call options by funds: $2.65M | Put options by funds: $842K
95% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 20
33% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 76
15% more capital invested
Capital invested by funds: $1.3B [Q2] → $1.5B (+$197M) [Q3]
8% more funds holding
Funds holding: 229 [Q2] → 247 (+18) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
3.1% less ownership
Funds ownership: 123.38% [Q2] → 120.28% (-3.1%) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$46
41%
upside
Avg. target
$48
48%
upside
High target
$50
54%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Needham Serge Belanger 46% 1-year accuracy 60 / 130 met price target | 41%upside $46 | Buy Upgraded | 10 Jan 2025 |
HC Wainwright & Co. Oren Livnat 50% 1-year accuracy 23 / 46 met price target | 54%upside $50 | Buy Reiterated | 10 Jan 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
Collegium Provides 2025 Financial Guidance and Business Update
– Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM ® Net Revenue Expected to be in Excess of $135 Million – – Adjusted EBITDA* Expected in the Range of $435 Million to $450 Million – – Adjusted Operating Expenses* Expected in the Range of $220 Million to $230 Million – STOUGHTON, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year financial guidance and provided a business update.
Positive
Seeking Alpha
2 months ago
Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion
Collegium Pharmaceutical's pain management portfolio, including Xtampza ER and Belbuca, drives 92.8% of revenues, demonstrating its market leadership in abuse-deterrent therapies. The acquisition of Jornay PM expands COLL's portfolio into neurology, tapping into the rapidly growing ADHD market, which is projected to reach $30.6 billion by 2032. Collegium reported strong Q3 2024 results, with 17% YoY revenue growth and EBIT margins improving to 35.2%, showcasing operational efficiency.
Neutral
GlobeNewsWire
2 months ago
Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)
MONTREAL, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved JORNAY PM™, an extended-release formulation of methylphenidate, a stimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in children.
Positive
Zacks Investment Research
2 months ago
Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Neutral
Zacks Investment Research
2 months ago
Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock?
Investors need to pay close attention to Collegium Pharmaceutical (COLL) stock based on the movements in the options market lately.
Neutral
Seeking Alpha
2 months ago
Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript
Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Danielle Jesse - Director, Investor Relations Michael Heffernan - Interim President and Chief Executive Officer, Founder and Chairman Scott Dreyer - Chief Commercial Officer Colleen Tupper - Chief Financial Officer Conference Call Participants Les Sulewski - Truist Securities David Amsellem - Piper Sandler Serge Belanger - Needham & Company Oren Livnat - H.C. Wainright Operator Greetings, and welcome to the Collegium Pharmaceutical Third Quarter 2024 Earnings Conference Call.
Neutral
Zacks Investment Research
2 months ago
Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings
While the top- and bottom-line numbers for Collegium Pharmaceutical (COLL) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Negative
Zacks Investment Research
2 months ago
Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Lag Estimates
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.61 per share, missing the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.34 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Collegium Reports Record Third Quarter 2024 Financial Results
– Generated Record Q3'24 Net Revenue of $159.3 Million, Up 17% Year-over-Year, Driven by Record Belbuca ® Revenue of $53.2 Million and Record Xtampza ® ER Revenue of $49.5 Million –
Positive
Zacks Investment Research
3 months ago
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charts implemented using Lightweight Charts™